Reckitt Benckiser (RBGLY) Stock Rating Reaffirmed by Deutsche Bank

Deutsche Bank restated their buy rating on shares of Reckitt Benckiser (OTCMKTS:RBGLY) in a research report released on Friday morning.

A number of other equities analysts have also issued reports on the stock. Credit Suisse Group reiterated a neutral rating on shares of Reckitt Benckiser in a research report on Tuesday, February 20th. Zacks Investment Research upgraded shares of Reckitt Benckiser from a strong sell rating to a hold rating in a research report on Wednesday, December 20th. JPMorgan Chase & Co. reiterated a buy rating on shares of Reckitt Benckiser in a research report on Monday, December 18th. Finally, Societe Generale upgraded shares of Reckitt Benckiser from a hold rating to a buy rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $21.00.

How to Become a New Pot Stock Millionaire

Reckitt Benckiser (OTCMKTS:RBGLY) opened at $16.83 on Friday. Reckitt Benckiser has a 12-month low of $15.80 and a 12-month high of $21.79. The company has a debt-to-equity ratio of 1.94, a quick ratio of 0.67 and a current ratio of 0.86.

ILLEGAL ACTIVITY NOTICE: “Reckitt Benckiser (RBGLY) Stock Rating Reaffirmed by Deutsche Bank” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3300858/reckitt-benckiser-rbgly-stock-rating-reaffirmed-by-deutsche-bank.html.

About Reckitt Benckiser

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl, and Strepsils brand names.

Analyst Recommendations for Reckitt Benckiser (OTCMKTS:RBGLY)

Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$0.22 EPS Expected for Career Education Co.  This Quarter
$0.22 EPS Expected for Career Education Co. This Quarter
Taseko Mines  Earning Somewhat Favorable Media Coverage, Study Finds
Taseko Mines Earning Somewhat Favorable Media Coverage, Study Finds
Brokerages Expect TherapeuticsMD Inc  to Post -$0.10 EPS
Brokerages Expect TherapeuticsMD Inc to Post -$0.10 EPS
Target Co.  Expected to Announce Earnings of $1.38 Per Share
Target Co. Expected to Announce Earnings of $1.38 Per Share
Zacks: Analysts Anticipate Marriott Vacations Worldwide Corp  Will Post Earnings of $1.50 Per Share
Zacks: Analysts Anticipate Marriott Vacations Worldwide Corp Will Post Earnings of $1.50 Per Share
OX Fina 1-Day Trading Volume Tops $2,287.00
OX Fina 1-Day Trading Volume Tops $2,287.00


© 2006-2018 Ticker Report. Google+.